| 2.64 -0.09 (-3.3%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.21  |
1-year : | 3.75 |
| Resists | First : | 2.75 |
Second : | 3.21 |
| Pivot price | 2.56 |
|||
| Supports | First : | 2.39 |
Second : | 2.17 |
| MAs | MA(5) : | 2.67 |
MA(20) : | 2.5 |
| MA(100) : | 2.25 |
MA(250) : | 2.24 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 89.7 |
D(3) : | 93.9 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 3.19 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PLX ] has closed below upper band by 33.1%. Bollinger Bands are 30.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.75 - 2.77 | 2.77 - 2.78 |
| Low: | 2.58 - 2.6 | 2.6 - 2.61 |
| Close: | 2.61 - 2.64 | 2.64 - 2.66 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Wed, 09 Sep 2026
Director at Protalix (NYSE: PLX) gets options expiring 2036 plus 8,500 RSUs - Stock Titan
Tue, 08 Sep 2026
Protalix CFO is scheduled for two New York appearances this month - Stock Titan
Tue, 08 Sep 2026
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences - Yahoo Finance
Fri, 04 Sep 2026
Yaron Naos awarded new equity at Protalix BioTherapeutics (PLX) - Stock Titan
Wed, 12 Aug 2026
Protalix BioTherapeutics, Inc. 2026: Revenue $19.9M, EPS $0.05— 10-Q Summary - TradingView
Wed, 12 Aug 2026
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|